设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

2023 年第 9 期 第 18 卷

妇科恶性肿瘤患者应用完全植入式静脉输液港相关并发症规避方法分享

Sharing of methods  for avoiding complications related to totally implantable venous access port in patients with gynecological malignant tumor

作者:于聪祥1李跃飞2张儒英1索静1赵荣伟1萨日娜1栗东海3谢晓亮4

英文作者:Yu Congxiang1 Li Yuefei2 Zhang Ruying1 Suo Jing1 Zhao Rongwei1 Sarina1 Li Donghai3 Xie Xiaoliang4

单位:1内蒙古医科大学附属医院妇产科,呼和浩特010050;2内蒙古自治区妇幼保健院妇产科,呼和浩特010050;3内蒙古医科大学附属医院甲乳外科,呼和浩特010050;4内蒙古医科大学附属医院介入科,呼和浩特010050

英文单位:1Department of Obstetrics and Gynecology the Affiliated Hospital of Inner Mongolia Medical University Hohhot 010050 China; 2Department of Obstetrics and Gynecology Maternal and Child Health Hospital of Inner Mongolia Autonomous Region Hohhot 010050 China; 3Department of Thyroid and Breast Surgery the Affiliated Hospital of Inner Mongolia Medical University Hohhot 010050 China; 4Interventional Department the Affiliated Hospital of Inner Mongolia Medical University Hohhot 010050 China

关键词:妇科恶性肿瘤;完全植入式静脉输液港;胸壁输液港;团队协作;全程管理

英文关键词:Gynecologicalmalignanttumor;Totallyimplantablevenousaccessport;Chestwallinfusionport;Teamcollaboration;Wholecoursemanagement

  • 摘要:
  • 癌症是危害居民健康的重大公共卫生问题。周期性化疗是妇科恶性肿瘤患者的主要治疗方式之一。应用安全、价格低廉以及放置和维护周期长的静脉输液装置是化疗药物发挥作用的重要保障,也是提高患者治疗效果和生活质量的重要保障。目前,完全植入式静脉输液港是妇科恶性肿瘤化疗中最常用的静脉输液通路,其在临床应用中可能发生术中及术后并发症。本文通过检索国内外文献并总结临床工作经验,对妇科恶性肿瘤应用完全植入式静脉输液港相关并发症的预防及管理进行总结,以期为临床妇科医护人员提供参考,推动中心静脉通路应用与管理方法的健康可持续发展。

  • Cancer is a major public health issue that threatens the health of residents. Periodic chemotherapy is one of the main treatment methods  for patients with gynecological malignant tumor. The application of safe, low-cost and long-placement-and-maintenance-cycle intravenous infusion devices is an important guarantee for the effectiveness of chemotherapy drugs, as well as an important guarantee for improving the treatment effect and the quality of life of patients. Currently, totally implantable venous access port (TIVAP) is the most commonly used central venous infusion access in gynecological malignant tumor chemotherapy, and may cause intraoperative and postoperative complications during clinical application. By searching domestic and foreign literatures and summarizing clinical experiences, this article summarizes the prevention and management of complications related to the application of TIVAP in gynecologic malignant tumor, in order to provide reference for clinical gynecological medical and nursing staff and promote the healthy and sustainable development of application and management methods  of central venous access.

copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭
Baidu
map